Crohn's Disease and Colitis Trial, Recruiting NCT07314606 Sponsor: University of British Columbia Condition: Crohn's Disease and Colitis
Back to Crohns Disease And Colitis

Crohn's Disease and Colitis Trial, Recruiting

NCT07314606
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with, or your doctor strongly suspects you have, moderate to severe Crohn's disease affecting the small intestine and/or large intestine, and your doctor plans to start you on a medication called infliximab.
  • Your Crohn's disease diagnosis was made within the last 12 months (at the time infliximab treatment begins).
  • You have never been treated with a biologic therapy (a specific type of medication that targets the immune system) before.
  • If you have had Crohn's disease for a while and are currently having a flare-up: your symptoms have not improved after 4 weeks of trying a special diet or steroid treatment.
  • If you have been newly diagnosed: your symptoms have not improved after 2 weeks of trying a special diet or steroid treatment.
  • Blood or stool tests show signs of active inflammation in your body (confirm with trial site for specific values).
  • Your body weight falls within a normal range for your age and sex (between the 5th and 95th percentile on standard growth/BMI charts).
  • You have been on steroids or exclusive enteral nutrition (a liquid-only diet) for less than 2 weeks (or less than 4 weeks if you have established disease).
  • You are able and willing to follow specific dietary recommendations as part of the trial.
  • You are taking a stable dose of azathioprine or methotrexate (immune-suppressing medications) at the time of joining the trial.
  • You are willing to also take part in a related research network study called CIDsCaNN.

Who may not be able to join:

  • You started a special Crohn's diet (CDED), liquid-only diet, or steroids more than 2 weeks before the point of joining the trial.
  • You have taken antibiotics in the last 2 months (except for a short course of less than 1 week taken between 1 and 2 months ago), or you have used laxatives in the past month (except as part of bowel preparation for a camera test before starting treatment).
  • You have taken probiotic, prebiotic, or synbiotic supplements in the last month (note: foods containing these, such as yogurt, are generally allowed — confirm with trial site).
  • You follow a strict vegetarian or vegan diet.
  • You are assessed as being at high risk of malnutrition based on a standard scoring tool used for children (confirm with trial site).
  • You have another known gut condition (other than irritable bowel syndrome), a food intolerance, or another long-term illness.
  • You have had bowel surgery before joining the trial.
  • You have severe disease around the anal area, or a type of Crohn's disease that causes narrowing or tunnelling through the bowel wall.
  • You have been taking prednisone or prednisolone (steroid medications) for more than 2 weeks.
  • You are currently pregnant or breastfeeding.
  • You are already taking part in another research study.
  • You are unable to give consent to participate (confirm with trial site regarding age or capacity requirements).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 15 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Kevan Jacobson, MBBCh, FRCP, FRCPC, AGAF, CAGF, The University of British Columbia

Phone: 604-875-2332

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
22 April 2026
Est. completion
1 October 2029

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

Clinical and biochemical response at the first infliximab (IFX) maintenance dose (week 12) in participants receiving mCDED alongside IFX compared with participants receiving IFX alone.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov